Evotec Advances in Neuroscience Partnership with Bristol Myers Squibb

Evotec SE has announced a significant milestone in its strategic neuroscience partnership with Bristol Myers Squibb. The company received a payment of $25 million for progress made in their collaborative efforts to develop treatments for neurodegenerative diseases. The payment will support further research and the growth of their joint program pipeline.

The collaboration, initiated in 2016, aims to discover disease-modifying treatments in a field with limited current options. It includes innovative programs like EVT8683, in-licensed by Bristol Myers Squibb in 2021, which has successfully completed Phase 1 clinical trials. This partnership was extended in 2023 for eight more years, underscoring the mutual commitment to advancing therapeutic options.

Evotec's Chief Scientific Officer, Dr. Cord Dohrmann, emphasized the urgent need for therapies that go beyond symptom management. This collaboration exemplifies the strategic integration of emerging disease biology into potential therapeutic solutions.